Skip to main content

Table 1 Characteristics of patients at commencement of interferon therapy

From: Long-term effects of peginterferon alfa-2a therapy in Japanese patients with chronic hepatitis B virus infection

Demographic data  
n 22
Sex, (female/male) 6/16
Age, years (range) 33 (22–50)
Previous treatment with interferon 6 (27.2 %)
Previous treatment with nucleoside analog 1 (1.7 %)
Laboratory Data
Aspartate aminotransferase, IU/L (range) 58 (28–237)
Alanine aminotransferase, IU/L (range) 111 (41–397)
Bilirubin, mg/dL (range) 0.7 (0.3-1.6)
Albumin, g/dL (range) 3.9 (3.5-4.4)
Platelets, ×103/μL (range) 196 (106–306)
HBsAg, (IU/ml) 2370 (22.1-75500)
Serum HBV DNA, log copies/mL (range) 7.6 (5.3 to >7.6)
HBeAg, positive/negative 17/5
HBV genotype (A/B/C) 2/2/18
  1. Data are median and (range) or number and (percentage)
  2. HBV hepatitis B virus, HBeAg Hepatitis B e antigen, ND not done